Clinical and translational research challenges in biliary tract cancers
Affiliation
Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester. United KingdomIssue Date
2020
Metadata
Show full item recordAbstract
BACKGROUND: Biliary tract cancers (BTC) are rare malignancies with a poor prognosis. There are many challenges encountered in treating these patients in daily practice as well as in clinical, translational and basic research. OBJECTIVE: This review summarises the most relevant challenges in clinical and translational research in BTCs and suggests potential solutions towards an improvement in quality of life and outcomes of patients diagnosed with such malignancies. FINDINGS: The main challenge is the low number of patients with BTCs, complicated by the aggressive natural behaviour of the cancer and the lack of funding sources for research. In addition, the clinical characteristics of these patients and the specific cancer-related complications challenge clinical research and clinical trial recruitment. It is worth highlighting that BTCs are a group of different malignancies (cholangiocarcinoma, gallbladder cancer and ampullary cancer) rather than a unique homogeneous disease. These subgroups differ not only in molecular aspects, but also in clinical and demographic characteristics. In addition, tailored imaging and quality of life assessment is required to tackle some of the issues specific to BTCs. Finally, difficulties in tissue acquisition both in terms of biopsy size and inclusion of sufficient tumour within the samples, may adversely impact translational and basic research. CONCLUSION: Increasing awareness among patients and clinicians regarding BTC and the need for further research and treatment development may address some of the main challenges in BTC research. International collaboration is mandatory to progress the field.Citation
Lamarca A, Frizziero M, McNamara MG, Valle JW. Clinical and translational research challenges in biliary tract cancers. Curr Med Chem. 2020.Journal
Current Medicinal ChemistryDOI
10.2174/0929867327666200123090153PubMed ID
31971102Additional Links
https://dx.doi.org/10.2174/0929867327666200123090153Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.2174/0929867327666200123090153
Scopus Count
Collections
Related articles
- The epidemiological trends of biliary tract cancers in the United States of America.
- Authors: Jiang Y, Jiang L, Li F, Li Q, Yuan S, Huang S, Fu Y, Yan X, Chen J, Li H, Li S, Liu J
- Issue date: 2022 Dec 29
- Biliary tract cancer incidence and trends in the United States by demographic group, 1999-2013.
- Authors: Van Dyke AL, Shiels MS, Jones GS, Pfeiffer RM, Petrick JL, Beebe-Dimmer JL, Koshiol J
- Issue date: 2019 May 1
- The state of therapy modalities in clinic for biliary tract cancer.
- Authors: Chen W, Hu Z, Song J, Wu Y, Zhang B, Zhang L
- Issue date: 2022 Jun 8
- Research progress of bile biomarkers and their immunoregulatory role in biliary tract cancers.
- Authors: Li YC, Li KS, Liu ZL, Tang YC, Hu XQ, Li XY, Shi AD, Zhao LM, Shu LZ, Lian S, Yan ZD, Huang SH, Sheng GL, Song Y, Liu YJ, Huan F, Zhang MH, Zhang ZL
- Issue date: 2022
- The expression of matrix metalloproteinases in intrahepatic cholangiocarcinoma, hilar (Klatskin tumor), middle and distal extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma: role of matrix metalloproteinases in tumor progression and prognosis.
- Authors: Kirimlioğlu H, Türkmen I, Başsüllü N, Dirican A, Karadağ N, Kirimlioğlu V
- Issue date: 2009 Mar